Pyroglutamic Acid (5-Oxoproline / Pidolic Acid): A Comprehensive Reference
1. Identity, Chemical Nature, and Nomenclature
Pyroglutamic acid (also known as PCA, 5-oxoproline, or pidolic acid) is a ubiquitous but understudied natural amino acid derivative in which the free amino group of glutamic acid or glutamine cyclizes to form a lactam. The names of its conjugate base, anion, salts, and esters are pyroglutamate, 5-oxoprolinate, or pidolate.
Pyroglutamic acid has the molecular formula C₅H₇NO₃ — the same as glutamic acid — but it contains a lactam ring with a highly dissociable carboxyl group. Unlike proline, which exists as a zwitterion at pH 7.4, pyroglutamic acid is completely dissociated at pH 7.4. The compound exists in two enantiomeric forms: the naturally predominant L-form and the synthetic D-form, both of which have been studied pharmacologically with distinct biological activities.
Additional systematic chemical names include:
- 2-pyrrolidone-5-carboxylic acid (2-pyrrolidinone-5-carboxylic acid)
- L-pyrrolidonecarboxylic acid (L-PCA)
- 5-oxo-L-proline
- Pidolic acid (the International Nonproprietary Name used in pharmaceutical contexts)
Pyroglutamic acid (pGlu; 5-oxoproline or pidolic acid) is a naturally occurring and little-investigated amino acid derivative that can be formed enzymatically or non-enzymatically, and has been observed to be widely synthesized in diverse living cells reported from archaebacteria to humans.
2. Historical Discovery and Early Scientific Characterization
The story of pyroglutamic acid begins with the broader investigation of glutamic acid in the nineteenth century. In 1866, the German chemist Karl Heinrich Ritthausen first isolated glutamic acid by treating wheat gluten with sulfuric acid, laying the groundwork for the subsequent identification of its cyclic derivative. Sixteen years later, in 1882, L. Haitinger reported the formation of a new substance when heating glutamic acid — a process of thermal dehydration resulting in the intramolecular cyclization of glutamic acid, yielding what is now known as pyroglutamic acid.
As first discovered in 1882, pyroglutamic acid can be formed by heating glutamic acid at 180 °C, which results in the loss of a molecule of water. This thermal dehydration reaction established a simple laboratory route to the compound long before its endogenous biosynthetic pathways were understood.
The formation of pyrrolidone carboxylic acid (PCA, pGlu) during protein biosynthesis was eventually documented, with studies demonstrating that PCA is formed during the later stages of biosynthesis — at the terminal phases of translation or as a post-translational event just prior to cellular secretion of protein with amino-terminal PCA. Of the studies cited, the most convincing evidence suggests that PCA is derived from glutamine.
3. Natural Sources and Occurrence
3.1 Endogenous Biosynthesis in Living Organisms
In living cells, pyroglutamic acid is derived from glutathione through the action of an enzyme, γ-glutamyl cyclotransferase. This positions PCA as a normal metabolite within the gamma-glutamyl cycle — the biochemical pathway responsible for amino acid transport across cell membranes and for glutathione synthesis and degradation. It is a metabolite in the glutathione cycle that is converted back to glutamate by 5-oxoprolinase.
Pyroglutamate is found in many proteins including bacteriorhodopsin. N-terminal glutamic acid and glutamine residues can spontaneously cyclize to become pyroglutamate, or can be enzymatically converted by glutaminyl cyclases. Enzymes which selectively remove PCA from the N-terminus have been isolated and shown to have a ubiquitous distribution in various animal and plant cells.
Pidolic acid is found in large quantities in brain tissue and other tissues in bound form, including skin.
3.2 Dietary and Food Sources
Pyroglutamic acid occurs naturally in many fruits, vegetables, and fermented foods (such as cheese and soy sauce), contributing to their savory depth. It is recognized as a contributor to the fifth taste quality, umami. When glutamine or glutamic acid residues at the N-terminal position of food proteins are exposed to heat, acid, or enzymatic treatment during fermentation and cooking processes, they cyclize spontaneously to pyroglutamate — a phenomenon well documented in aged cheeses, fish sauces, miso, and long-cooked meat broths.
In human skin, pyroglutamic acid is generated endogenously through the proteolysis of filaggrin. Filaggrin, coded by the FLG gene, is the main source of several major components of natural moisturizing factor (NMF) in the stratum corneum, including pyrrolidone carboxylic acid (PCA) and urocanic acid (UCA). Enzymatic degradation of the binding protein filaggrin results in stratum corneum localization of free amino acids, notably histidine, glutamine, arginine, and their derivatives, urocanic acid, pyroglutamic acid or 2-pyrrolidone-5-carboxylic acid (PCA), and urea/ornithine.
4. Common Forms and Preparations
Pyroglutamic acid is commercially available and studied in several forms:
- Free acid (L-pyroglutamic acid): L-pyroglutamic acid is sold online as a nootropic dietary supplement.
- Arginine salt (arginine pyroglutamate): The arginine salt form has been extensively used in animal cognition studies and in some human investigations, offering improved solubility.
- Sodium pyroglutamate (sodium PCA / sodium pidolate): The sodium salt of pyroglutamic acid — known either as sodium pyroglutamate, sodium PCA, or sodium pidolate — is used in dry skin and hair products, as it is a humectant.
- Magnesium pidolate (magnesium pyroglutamate): Magnesium pidolate, the magnesium salt of pidolic acid (also known as pyroglutamic acid), is a mineral supplement containing 8.6% magnesium w/w.
- Topical esters: Compositions containing esters of pyroglutamic acid have been developed for topical application to human skin or hair; pyroglutamic acid (also known as 2-pyrrolidone-5-carboxylic acid) is the principal ingredient of the natural moisturizing factor that enables the stratum corneum to maintain a high water content despite low external humidity, though pyroglutamic acid applied topically has a temporary moisturizing effect and is easily washed away.
- DMAE pyroglutamate (dimethylaminoethanol pyroglutamate): DMAE p-Glu is a compound resulting from the reaction between dimethylaminoethanol (an indirect precursor of acetylcholine) and pyroglutamic acid (a cyclic derivative of glutamic acid having procholinergic properties and promnesic effects in both animals and man).
Pyroglutamic acid has low toxicity and is not a skin irritant, but its use in cosmetic products is limited by a high price.
5. Biochemical Role and Mechanisms of Action
5.1 The Gamma-Glutamyl Cycle and Glutathione Metabolism
Pyroglutamic acid (as 5-oxoproline) occupies a pivotal node in the gamma-glutamyl cycle. The enzymes that comprise the γ-glutamyl cycle are widely distributed in the body, with the highest enzyme activities in organs with very active amino acid transport such as the kidney, liver, and small bowel. In this cycle, glutathione is split and reformed in the process of transporting amino acids into cells; γ-glutamyl cyclotransferase acts on gamma-glutamyl amino acid conjugates to liberate pyroglutamic acid as an intermediate, which is then converted back to glutamate by the ATP-dependent enzyme 5-oxoprolinase.
Pyroglutamic acid may function in glutamate storage, and acts to oppose the action of glutamate, including in the brain.
5.2 Cholinergic Mechanisms
A well-characterized mechanism relevant to its nootropic properties is interaction with the central cholinergic system. Animal studies established that PCA can modulate acetylcholine levels in the brain. Scopolamine (a muscarinic antagonist) brought about a 52% and 39% decrease, respectively, in cortical and hippocampal acetylcholine levels; D,L-pyroglutamic acid at doses of 500 and 1000 mg/kg also prevented this decrease in brain acetylcholine level. In conclusion, D,L-PCA is active on cortical and hippocampal cholinergic mechanisms and, like other 2-oxopyrrolidone derivatives, shows cognition-enhancing properties.
Pyroglutamic acid may function in glutamate storage, acts to oppose the action of glutamate in the brain, and also acts on the brain's cholinergic system.
5.3 Glutamatergic Transport and Neuronal Uptake
Pyroglutamic acid is actively transported in neural tissue. The presence of an efficient uptake system for L-pyroglutamate was demonstrated in cultured glial cells originating from newborn rats; it is also transported by a high-affinity uptake mechanism in neurons cultured from rat embryo cerebral hemispheres, although with a Vmax 6 times lower than for glial cells. L-pyroglutamate, like L-glutamate, is preferentially transported by glial cells, but with a Vmax 40 to 60 times lower than for glutamate. Pyroglutamate is more actively metabolized in glial cells than in neurons, and glutamate is the main metabolite.
A regional distribution study of the uptake processes for L-³H-glutamic acid and L-³H-pyroglutamic acid in different areas of the brain showed a similar distribution, suggesting that uptake of pyroglutamic acid — although weak — occurs in glutamatergic nerve terminals, with results showing that the uptake of pyroglutamic acid, as for glutamic acid, mainly occurred in corticostriatal nerve terminals.
5.4 Enzyme Inhibition: PDE5, ACE, and Urease
A 2019 multi-biochemical and in silico study published in Biomolecules (PMC6770154) tested pyroglutamic acid against three important enzyme targets. Pyroglutamic acid (pGlu) efficiently inhibited the catalytic activities of three important enzymes: human recombinant phosphodiesterase-5A1 (PDE5A1), human angiotensin-converting enzyme (ACE), and urease — enzymes associated with several important clinical conditions in humans. The results unveiled that pGlu potently suppressed the activity of PDE5A1 with an IC₅₀ of 5.23 µM compared with that of standard drug sildenafil citrate (IC₅₀ = 7.14 µM); moreover, pGlu at a concentration of 20 µg/mL was found to efficiently inhibit human ACE with 98.2% inhibition compared with that of standard captopril (99.6% at 20 µg/mL). These findings are biochemical/in vitro only; no human clinical data exist for these enzyme-inhibitory actions and additional studies are required to be performed against all PDE families to verify the selectivity of pGlu against PDE5A1, and the mechanism by which pGlu induced anti-PDE5A1 activity should be explored in further investigations.
6. Traditional and Historical Use
Pyroglutamic acid does not have a clearly documented history of use as an isolated compound in any pre-modern traditional medicine system, which is unsurprising given that it was first identified only in 1882 and that its chemical characterization required modern analytical techniques. Its traditional "exposure" to human populations has been dietary — through the consumption of fermented and protein-rich foods — rather than as a deliberately administered therapeutic agent.
Its pharmaceutical investigation began earnestly in Europe (particularly Italy and France) in the 1970s through the 1990s, when researchers explored it as a cognition enhancer in the context of preclinical neuropharmacology. European pharmaceutical researchers, notably in the context of investigating compounds structurally related to piracetam (a 2-oxopyrrolidone derivative), systematically studied the arginine salt of pyroglutamic acid for its pro-mnemonic properties in aged animals and humans. This period represents the closest analog to a "traditional" therapeutic context for the compound — a 20th-century European pharmaceutical tradition of rational drug discovery rather than folk medicine.
In dermatological and cosmetic science, pyroglutamic acid (as pyrrolidone carboxylic acid or PCA) has been incorporated into topical preparations since at least the 1970s, following the recognition of its role as a component of the skin's natural moisturizing factor.
7. Scientific Evidence by Area of Use
7.1 Cognitive Function and Memory Enhancement
Animal (Preclinical) Studies
The most substantial body of experimental data on pyroglutamic acid's cognitive effects comes from rodent studies. The effects of the arginine salt of pyroglutamic acid (2-oxo-pyrrolidone carboxylic acid, PCA) on learning and memory capacities of old rats were studied in a subchronic treatment schedule (intraperitoneal injection of 0.1 and 1 g/kg/day for 15 days); acquisition and extinction of active avoidance behaviour were studied in a pole-jumping test, and retention of passive avoidance response was examined in a step-through task. PCA facilitated the rate of acquisition of pole-jumping response and inhibited its extinction; the dose of 1 g/kg was more potent than 0.1 g/kg. In the passive avoidance task, treatment with PCA was followed by improved avoidance retention, indicating that PCA is a behaviourally active compound that improves learning and memory capacities in old rats.
Studies with scopolamine-induced amnesia confirmed a cholinergic mechanism. D,L-pyroglutamic acid at 500 and 1000 mg/kg, administered as arginine salt 120 minutes before retesting, prevented both electroconvulsive shock- and scopolamine-induced amnesia; arginine alone was ineffective. When the two isomers were studied separately, D-PCA was more effective than L-PCA and antagonized scopolamine-induced amnesia at doses of 250 and 500 mg/kg.
Human Clinical Studies
Evidence is limited to a small number of older trials with small sample sizes.
The key published human trial is that of Grioli et al. (1990), published in Fundamental & Clinical Pharmacology. In a randomized, double-blind trial, pyroglutamic acid (PCA) was compared with placebo for assessing its efficacy in treating memory deficits in 40 aged subjects; twenty subjects were treated with PCA and 20 with placebo over a period of 60 days, with memory functions evaluated at baseline and after treatment by means of a battery of 6 memory tasks. The results suggest that PCA is effective in improving some verbal memory functions in subjects affected by age-related memory decline. This trial's small size (n = 40), absence of modern neuropsychological assessment tools, and single-site design limit the strength of its conclusions.
A combined preclinical and clinical study of DMAE pyroglutamate (a derivative compound) evaluated its effects on scopolamine-induced cognitive impairment. The clinical study examined the effect of DMAE p-Glu on cognitive deficits induced by an intravenous injection of scopolamine in healthy young male subjects; results indicate that DMAE p-Glu reduces the deleterious effect of scopolamine on long-term memory in healthy volunteers and suggest that DMAE p-Glu might be effective in reducing memory deficits in patients with cognitive impairment. It should be noted that this study used a derivative compound (DMAE pyroglutamate), not free pyroglutamic acid; scopolamine challenge is a pharmacological model, not naturalistic age-related cognitive decline; and the population studied were healthy young males, not older adults with established cognitive impairment.
Overall evidence rating for cognition in humans: weak to preliminary. The available human clinical data are few in number, old, conducted in small populations, and have not been replicated by adequately powered, modern randomized controlled trials. No Cochrane reviews or systematic reviews specifically address L-pyroglutamic acid supplementation for cognitive outcomes in humans.
7.2 Skin Hydration and the Natural Moisturizing Factor
This is the area with the most robust, mechanistically well-understood evidence, though it relates primarily to endogenous PCA generated in skin rather than supplemental oral intake.
Pyroglutamic acid is a natural humectant in skin, and part of its natural moisturizing factor (NMF). Natural moisturizing factor is essential for appropriate stratum corneum hydration, barrier homeostasis, desquamation, and plasticity; it is formed from filaggrin proteolysis into small, hygroscopic molecules including amino acids.
Filaggrin can be degraded to free amino acids forming a major component of natural moisturizing factor (NMF), which serves as the primary humectant of the stratum corneum; 2-pyrrolidone-5-carboxylic acid (PCA) and urocanic acid (UCA) are two important NMF components, which bind water and make the surface of normal skin soft and flexible. Filaggrin, together with NMF, contribute to stratum corneum hydration and pH, and function to improve the skin barrier and water-binding capability of the epidermis. Decreased filaggrin and NMF are the key factors resulting in dry skin.
The relevance to skin disease is clinically supported by research in atopic dermatitis. Filaggrin, coded by FLG, is the main source of several major components of NMF in the stratum corneum, including PCA and UCA; loss-of-function mutations in FLG lead to reduced levels of filaggrin degradation products in the SC. This genetic linkage reinforces PCA's physiological importance to skin barrier integrity.
Topically applied sodium pyroglutamate (sodium PCA) is well established as an effective humectant in cosmetic formulations. The sodium salt of pyroglutamic acid is used in dry skin and hair products as a humectant; it has low toxicity and is not a skin irritant, but its use in products is limited by a high price. Pyroglutamic acid applied topically to the skin has a temporary moisturizing effect, but it is easily washed away and gives no long-term skin benefit. This limitation has driven the development of ester forms of PCA for more durable topical delivery.
Overall evidence rating for skin hydration: Strong mechanistic evidence for the endogenous role of PCA in skin moisturization through filaggrin proteolysis and the NMF. Evidence for topical sodium PCA as a cosmetic humectant is well-established. Evidence for oral PCA supplementation improving skin hydration is absent from the peer-reviewed literature.
7.3 Pyroglutamate-Modified Amyloid-β and Alzheimer's Disease
A distinct and important area of research — largely separate from the use of PCA as a dietary supplement — concerns the pathological role of pyroglutamate-modified amyloid-beta (pGlu-Aβ) peptides in Alzheimer's disease (AD). This does not represent a therapeutic application of pyroglutamic acid, but rather a disease-relevant biochemical modification involving pyroglutamate.
N-terminally truncated, pyroglutamate-modified amyloid-β (Aβ) peptides are major constituents of amyloid deposits in Alzheimer's disease. The main amyloid-β peptide variants detected in the human brain are Aβ1-40 and Aβ1-42; however, a significant proportion of Aβ in Alzheimer's disease brain also consists of N-terminal truncated/modified species. AβN3(pE), an Aβ peptide bearing amino-terminal pyroglutamate at position 3, has been demonstrated to be a major N-truncated/modified constituent of intracellular, extracellular, and vascular Aβ deposits in AD and Down syndrome brain tissue.
Pyroglutamate-modified Aβ peptides have been demonstrated to be the predominant components among all N-terminal truncated Aβ species in AD brains and represent highly desirable and abundant therapeutic targets. The current research describes the properties and localization of two pyroglutamate-modified Aβ peptides, AβN3(pE) and AβN11(pE), in the brain; the role of glutaminyl cyclase (QC) in the formation of these peptides is also addressed, along with two potential therapeutic strategies — the inhibition of QC and immunotherapy approaches — and clinical trials aimed at targeting these pathological Aβ species are reviewed.
Research has tested differences in the aggregation kinetics of Aβ1-42, Aβpy3-42, and Aβpy11-42 found in different relative concentrations in brains in normal aging and in Alzheimer's disease; substantially faster aggregation kinetics were found for Aβpy3-42. This behavior is due to the particular sequence of this peptide, which is also responsible for specific oligomeric aggregation states very different from Aβ1-42, the latter being more prone to fibril formation.
A pilot study on CSF from elderly individuals with subjective memory complaints, mild cognitive impairment, and Alzheimer's disease demonstrated that five N-terminally truncated forms including pyroglutamate-modified Aβ isoforms, along with Aβ1-42, are altered in AD/MCI and are potential markers of AD progression.
Post-translationally modified N-terminally truncated amyloid beta peptide with a cyclized form of glutamate at position 3 (pE₃Aβ) is a highly pathogenic molecule with increased neurotoxicity and propensity for aggregation; in the brains of Alzheimer's disease cases, pE₃Aβ represents a major constituent of the amyloid plaque. The data show that pE₃Aβ formation is increased at early pre-symptomatic disease stages, while tau phosphorylation and aggregation mostly occur at later stages, suggesting that pE₃Aβ accumulation may be an early event in disease pathogenesis.
Overall evidence rating: The pathological role of pGlu-Aβ in Alzheimer's disease is supported by multiple lines of evidence from human post-mortem brain studies, CSF biomarker studies, and animal models. This research direction is currently focused on developing diagnostic tools and therapeutic targets (QC inhibitors, immunotherapy) rather than on supplemental pyroglutamic acid.
7.4 Anxiolytic Properties
Animal studies, primarily from the late 1980s, suggest potential anxiolytic activity for the L-isomer. By use of a simple anticonflict procedure (Vogel test), it was demonstrated that L-pyroglutamic acid (L-pyrrolidone carboxylic acid [L-PCA]), an amino acid naturally occurring in mammalian tissues and fluids, possesses anxiolytic activity. This effect was stereospecific (D-PCA was inactive) and in the rat was not associated with a decrease in motor activity; a benzodiazepine antagonist (Ro 15-1788) did not modify L-PCA actions; furthermore, anxiolytic doses of the amino acid did not change the content of 5-hydroxytryptamine (5-HT) or 5-hydroxyindoleacetic acid (5-HIAA) in the rat cortex and hippocampus. These results suggest that the mechanism of the anxiolytic activity of L-PCA is different from that of the benzodiazepines and of 5-HT1a agonists.
Overall evidence rating for anxiolytic effects in humans: absent. All available evidence is from preclinical animal models. No human clinical trials evaluating anxiolytic effects of pyroglutamic acid supplementation were identified in the peer-reviewed literature.
7.5 Magnesium Delivery and Mineral Bioavailability
One of the most clinically documented supplement applications of pyroglutamic acid is as a carrier salt for magnesium. Magnesium pidolate is a chelated form of magnesium where the mineral is bound to pidolic acid (pyroglutamic acid), a derivative of glutamic acid; it is prized primarily for its high bioavailability and good gastrointestinal tolerability, making it a preferred supplement for those seeking to improve magnesium status without the common digestive side effects such as diarrhea often associated with other magnesium salts.
The historical development of this application is traceable to European pharmaceutical research. French researchers at Pierre Fabre Laboratories advanced this work in the 1970s, focusing on glutamic acid derivatives to enhance mineral absorption, leading to the identification of magnesium pidolate as a stable, bioavailable form suitable for pharmaceutical applications; by the early 1980s, animal trials demonstrated superior bioavailability compared to inorganic magnesium salts, with studies showing effective tissue uptake and reduced gastrointestinal side effects in rodent models of deficiency.
A published clinical trial examined magnesium pidolate in patients with sickle cell disease. This trial (De Franceschi et al., 2000, British Journal of Haematology, PMID 10691856) evaluated long-term oral magnesium pidolate administration in sickle cell patients, a population in whom magnesium deficiency and abnormal erythrocyte cation transport are clinically significant features. The principle underpinning the pidolate carrier is that pyroglutamic acid may facilitate transport of magnesium across intestinal and cellular membranes more efficiently than inorganic counterparts.
Overall evidence rating for magnesium pidolate: Plausible and preliminary clinical evidence. The bioavailability advantage is supported by mechanistic and animal data; human clinical trials are limited in number and scope. Magnesium pidolate is an approved and marketed pharmaceutical/supplement ingredient in several European countries.
7.6 In Vitro Enzyme Inhibition and Anti-Enzymatic Properties
A 2019 study published in Biomolecules (DOI: 10.3390/biom9090392) examined pGlu against PDE5A1, ACE, and urease using radioactivity-based, spectrophotometric, and ESI-mass spectrometry methods. It exhibits strong angiotensin-converting enzyme (ACE) inhibition achieving 98.2% inhibition at 20 µg/mL, which supports its exploration for hypertension treatment by reducing angiotensin II formation; pyroglutamic acid also inhibits urease with an IC₅₀ of 1.8 µM, offering potential relevance against Helicobacter pylori infections, as urease is essential for the bacterium's gastric colonization.
Important caveat: These are purely in vitro (cell-free enzymatic) findings. They do not establish clinical efficacy and require substantial further investigation before any therapeutic conclusions can be drawn.
8. Body Systems and Health Areas of Association
- Central nervous system: Cognitive function, memory, anxiolytic activity (primarily preclinical); Alzheimer's disease pathology (pyroglutamate-modified Aβ); glutamatergic and cholinergic neurotransmission; uptake in glial and neuronal cells.
- Integumentary system (skin): Endogenous component of NMF in the stratum corneum; skin hydration and barrier function; cosmetic humectancy via sodium PCA.
- Metabolic/biochemical: Intermediate in the gamma-glutamyl cycle; linked to glutathione synthesis and catabolism; metabolic acidosis (pathological elevation).
- Cardiovascular/renal system: ACE inhibition (in vitro only); relevance to magnesium status and cardiac/muscular function via magnesium pidolate supplementation.
- Gastrointestinal: Urease inhibition (in vitro only); potential theoretical relevance to H. pylori colonization.
9. Dosage Forms and Doses Reported in Studies
The following dosages are reported directly from published sources and should not be interpreted as recommendations:
- Animal cognition studies: The arginine salt of pyroglutamic acid was studied in old rats via intraperitoneal injection at 0.1 and 1 g/kg/day for 15 days.
- Scopolamine amnesia model (rats): D,L-pyroglutamic acid (as arginine salt) at 500 and 1000 mg/kg administered 120 minutes before retesting prevented both ECS and scopolamine-induced amnesia.
- Human memory trial (Grioli et al., 1990): In a randomized, double-blind trial in 40 aged subjects, 20 subjects were treated with PCA and 20 with placebo over 60 days; memory functions were evaluated at baseline and after 60 days by a battery of 6 memory tasks. The specific gram dose per day used in this human trial was not reported in the available abstract text.
- In vitro enzymatic inhibition: pGlu demonstrated an IC₅₀ of 5.23 µM against PDE5A1; at a concentration of 20 µg/mL it produced 98.2% inhibition of human ACE. These are cell-free assay concentrations, not clinical doses.
- Dietary intake: No official Recommended Dietary Allowance (RDA) exists for pyroglutamic acid.
- Magnesium pidolate: Magnesium pidolate contains 8.6% magnesium w/w, and dosing in supplement use is governed by the desired elemental magnesium intake rather than by the pidolate moiety specifically.
10. Safety Considerations and Drug Interactions
10.1 Pathological Elevation: 5-Oxoprolinuria
The most thoroughly documented safety concern relating to pyroglutamic acid is not from exogenous supplementation but from pathological endogenous overproduction. A growing number of case reports and case series describe high anion gap metabolic acidosis (HAGMA) following paracetamol exposure with subsequent detection of 5-oxoproline (pyroglutamic acid) in blood, urine, or both; typically, 5-oxoprolinuria or 5-oxoprolinemia occurs in the setting of inborn genetic errors in glutathione metabolism.
The acquired form of 5-oxoproline metabolic acidosis was first described in 1989 and its relationship to chronic acetaminophen ingestion was proposed the next year; since then, this cause of chronic anion gap metabolic acidosis has been increasingly recognized, though many cases go unrecognized because an assay for 5-oxoproline is not widely available. Most cases occur in malnourished, chronically ill women with a history of chronic acetaminophen ingestion.
An acquired deficiency of glutathione secondary to paracetamol ingestion results in loss of negative feedback and enhances the production of 5-oxoproline, leading to metabolic acidosis and 5-oxoprolinuria. Acetaminophen levels are very rarely in the toxic range in such cases; rather, they are usually therapeutic or low. The disorder generally resolves with cessation of acetaminophen and administration of intravenous fluids. Methionine or N-acetyl cysteine may accelerate resolution and methionine is protective in a rodent model.
10.2 Genetic Metabolic Disorders
Chronic elevation of L-pyroglutamic acid concentrations is associated with several genetic metabolic disorders, including 5-oxoprolinuria and glutathione synthetase deficiency, which can lead to severe health complications; when levels exceed normal thresholds, arterial pH may drop below 7.35, causing various symptoms. In infants, symptoms may include poor feeding, vomiting, hypotonia, and lack of energy, which can progress to severe outcomes such as seizures or organ failure.
At least two genetic enzyme defects lead to the overproduction of 5-oxoproline: inherited abnormalities of 5-oxoprolinase (autosomal recessive traits) cause the accumulation of 5-oxoproline, generating 5-oxoprolinemia and 5-oxoprolinuria; clinical manifestations include neonatal hypoglycemia, microcytic anemia, and intellectual deficits.
10.3 Drug Interactions
Concomitant use of flucloxacillin, another medication associated with oxoprolinemia or oxoprolinuria, has been found to confound cases of paracetamol-associated HAGMA. It is likely that the propensity for HAGMA following paracetamol exposure may be genetically determined. Clinicians evaluating unexplained high anion gap metabolic acidosis should consider 5-oxoprolinemia, particularly in patients receiving chronic acetaminophen or flucloxacillin therapy.
10.4 In Vitro Cytotoxicity
The 2019 PMC study (PMC6770154) by Šudomová et al. also evaluated cytotoxicity of pGlu in human cell lines. The findings suggested low cytotoxicity at concentrations used for enzymatic inhibition, consistent with the longstanding characterization of the compound as having low intrinsic toxicity. Pyroglutamic acid has low toxicity and is not a skin irritant.
10.5 High-Dose Neurological Effects (Preclinical)
One rat study investigated in vitro effects of high concentrations of L-pyroglutamic acid in cerebral cortex. In a study investigating effects of L-pyroglutamic acid (PGA) — which predominantly accumulates in the inherited metabolic diseases glutathione synthetase deficiency and gamma-glutamylcysteine synthetase deficiency — PGA significantly reduced brain CO₂ production by 50% at concentrations of 0.5 to 3 mM, lipid biosynthesis by 20%, and ATP levels by 52% at the concentration of 3 mM. These in vitro findings used concentrations relevant to the pathological accumulation seen in inborn errors of metabolism rather than to dietary or supplemental exposure.
11. Protein Biochemistry: N-Terminal Pyroglutamate and Sequencing Challenges
N-terminal glutamic acid and glutamine residues can spontaneously cyclize to become pyroglutamate, or be enzymatically converted by glutaminyl cyclases. This is one of several forms of blocked N-termini which present a problem for N-terminal sequencing using Edman chemistry, which requires a free primary amino group not present in pyroglutamic acid. The enzyme pyroglutamate aminopeptidase can restore a free N-terminus by cleaving off the pyroglutamate residue.
Pyroglutamic acid formation from N-terminal glutamic acid has been identified in the heavy chains and light chains of several antibodies, indicating that this nonenzymatic reaction occurs very commonly and can be detected after a few weeks of incubation at 37°C and 45°C; the rate of this reaction was measured in aqueous buffers with different pH values, showing minimal formation at pH 6.2 and increased formation at pH 4 and pH 8. This process has significant implications for the biopharmaceutical industry in the manufacture and quality control of therapeutic monoclonal antibodies.
12. Summary of Evidence Strength by Application
- Skin barrier hydration (endogenous NMF component): Well-established physiological role, supported by multiple high-quality biochemical and clinical dermatology studies.
- Topical humectancy (sodium PCA in cosmetics): Well-supported within cosmetic science; temporary effect only.
- Cognitive / memory effects in animals: Consistent preclinical evidence across multiple rodent paradigms; mechanism linked to cholinergic modulation.
- Cognitive / memory effects in humans: Preliminary and limited; single small randomized controlled trial (n=40, 1990); no modern replications identified.
- Anxiolytic effects: Animal data only; no human trials identified.
- Enzyme inhibition (ACE, PDE5, urease): In vitro data only; no human pharmacological studies.
- Magnesium pidolate for magnesium supplementation: Supported by plausible pharmacokinetic rationale and limited clinical use data; evidence base comparable to other organic magnesium salts.
- Pathological accumulation and metabolic acidosis: Well-documented in clinical case reports and case series; relevant primarily to individuals with inborn errors of glutathione metabolism or chronic acetaminophen/flucloxacillin use.
- Alzheimer's disease (pGlu-Aβ as pathological species): Substantial converging evidence from human post-mortem, CSF biomarker, and animal model data; this represents a disease mechanism, not a therapeutic target for supplemental PCA.
References
Go back